Citadel Advisors
PTGX icon

Citadel Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Citadel Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.14M Sell
48,800
-40,000
-45% -$3.54M ﹤0.01% 4289
2025
Q4 		$7.76M Buy
88,800
+63,600
+252% +$5.21M ﹤0.01% 3604
2025
Q3 		$1.67M Buy
25,200
+13,300
+112% +$756K ﹤0.01% 6441
2025
Q2 		$658K Sell
11,900
-39,300
-77% -$1.89M ﹤0.01% 7990
2025
Q1 		$2.48M Buy
51,200
+42,400
+482% +$1.78M ﹤0.01% 5123
2024
Q4 		$340K Buy
8,800
+2,000
+29% +$87.2K ﹤0.01% 9404
2024
Q3 		$306K Sell
6,800
-600
-8% -$24.2K ﹤0.01% 9296
2024
Q2 		$256K Sell
7,400
-3,500
-32% -$103K ﹤0.01% 9440
2024
Q1 		$315K Sell
10,900
-331,700
-97% -$9.03M ﹤0.01% 9353
2023
Q4 		$7.86M Buy
342,600
+11,100
+3% +$194K ﹤0.01% 3157
2023
Q3 		$5.53M Sell
331,500
-16,900
-5% -$328K ﹤0.01% 3508
2023
Q2 		$9.62M Sell
348,400
-51,100
-13% -$1.28M ﹤0.01% 2729
2023
Q1 		$9.19M Buy
399,500
+72,000
+22% +$1.21M ﹤0.01% 2921
2022
Q4 		$3.57M Sell
327,500
-10,300
-3% -$86.9K ﹤0.01% 4458
2022
Q3 		$2.85M Sell
337,800
-204,500
-38% -$1.94M ﹤0.01% 4903
2022
Q2 		$4.29M Buy
542,300
+417,600
+335% +$5.05M ﹤0.01% 4093
2022
Q1 		$2.95M Buy
124,700
+55,000
+79% +$1.55M ﹤0.01% 5223
2021
Q4 		$2.38M Sell
69,700
-15,800
-18% -$499K ﹤0.01% 5833
2021
Q3 		$1.51M Buy
85,500
+71,600
+515% +$3.05M ﹤0.01% 7062
2021
Q2 		$624K Buy
13,900
+3,900
+39% +$129K ﹤0.01% 9523
2021
Q1 		$259K Buy
+10,000
New +$253K ﹤0.01% 11166

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Citadel Advisors's PTGX Position: Q1 2026 in Review

Citadel Advisors increased its Protagonist Therapeutics (PTGX) stake by 38% in Q1 2026, buying an estimated $37.6M and bringing the position to 1,551,900 shares worth $164M. The position accounts for 0.03% of the portfolio, ranked #545.

Citadel Advisors first reported a position in PTGX in Q1 2018 and has held it in 30 quarters since. 318 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Citadel Advisors held 1,551,900 shares of Protagonist Therapeutics worth $164M as of Q1 2026.
  • Citadel Advisors bought 425,213 Protagonist Therapeutics shares in Q1 2026, an estimated $37.6M.
  • Protagonist Therapeutics made up 0.03% of Citadel Advisors's portfolio in Q1 2026, its #545 holding.
  • Citadel Advisors first reported a position in Protagonist Therapeutics in Q1 2018 and has held it in 30 quarters since.
  • 318 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.